Browsing eNauka
Browsing by Author Bril, Vera
Showing results 1 to 9 of 9
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2021 | Analysis of Efgartigimod Efficacy Across Patient Populations and Myasthenia Gravis Specific Scales: Results of the Phase 3 ADAPT Study![]() | Bril, Vera; ...; Perić, Stojan Z. | Conference Paper | Mp. category will be shown later |
| 2022 | Efficacy, Safety, and Tolerability of Efgartigimod in Acetylcholine Receptor Autoantibody Seronegative Patients with Generalized Myasthenia Gravis: Integrated Interim Analysis of the Adapt and Adapt plus Studies![]() | Howard, James F Jr; Bril, Vera; Tuan, Vu; Karam, Chafic; Perić, Stojan Z.
Guglietta, Antonio; T'joen, Caroline; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato;
| Conference Paper | Mp. category will be shown later |
| 2021 | Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study![]() | Howard, James; Bril, Vera; Vu, Tuan; Karam, Chafic; Perić, Stojan Z.
Verschuuren, Jan JGM; Mantegazza, Renato;
| Conference Paper | Mp. category will be shown later |
| 2023 | Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study | Hadden, R; Andersen, H; Bril, Vera; Basta, Ivana Z; Rejdak, Konrad; Djordjevic, Goran D; Greco, E; Hasan, S; French, J; Yel, L;
Ay, H;
| Conference Paper | Mp. category will be shown later |
| 2024 | Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% for CIDP: Final Results from a Long-Term Safety and Tolerability Study | Hadden, Robert; Andersen, Henning; Bril, Vera; Basta, Ivana Z; Rejdak, Konrad; Duff, Kim; Greco, Erin; Hasan, Shabbir; Anderson, Smits Colin; Ay, Hakan | Conference Paper | Mp. category will be shown later |
| 2022 | Long-Term Assessment of Efgartigimod in Patients with Generalised Myasthenia Gravis: Adapt Plus Study Interim Results![]() | Jacob, Saiju; Howard, James F Jr; Bril, Vera; Perić, Stojan Z. | Конференцијски рад | Мп категорија ће бити приказана накнадно. |
| 2024 | Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial | Hadden, Robert DM; Andersen, Henning; Bril, Vera; Basta, Ivana; Rejdak, Konrad; Duff, Kim; Greco, Erin; Hasan, Shabbir; Anderson, Smits Colin; Ay, Hakan | Научни чланак | 21M21 - Водећи међународни часопис категорије M21 |
| 2023 | Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT+ study![]() | Bril, Vera; ...; Perić, Stojan Z. | Конференцијски рад | Мп категорија ће бити приказана накнадно. |
| 2022 | Long-Term Safety, Tolerability, and Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Interim Results of the Adapt plus Study![]() | Howard, James F Jr.; Bril, Vera; Tuan, Vu; Karam, Chafic; Perić, Stojan Z.
Guglietta, Antonio; T'joen, Caroline; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato;
| Conference Paper | Mp. category will be shown later |
